IMR Press / FBE / Volume 4 / Issue 8 / DOI: 10.2741/E580

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


CD24, COX-2, and p53 in epithelial ovarian cancer and its clinical significance

Show Less
1 Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 200040, China
2 Shanghai Tumor Hospital, Fudan University, Shanghai 200032, China

*Author to whom correspondence should be addressed.


Front. Biosci. (Elite Ed) 2012, 4(8), 2645–2651;
Published: 1 June 2012

Epithelial ovarian cancer (EOC) prognosis is associated with International Federation of Gynecology and Obstetrics (FIGO) staging, cancer cell classification, patient age, and residual tumor size. However, the molecular markers for predicting EOC prognosis remain to be explored. In this study, we investigated the expression of CD24, COX-2, and p53 in EOC, and their relationships to clinical prognosis. We found that the expression of CD24 was detected in the cell membrane in 90.6% (58/64) of EOC cases and in the cytoplasm in 54.7% (35/64) of EOC cases; 78.6% (11/14) cases of borderline tumors had CD24- positive staining in the cell membrane. All 9 cases of benign tumors were negative for CD24 staining. Expression of CD24 correlated with the nuclear expression of p53, but not with the expression of COX-2. Overexpression of CD24 is an independent factor associated with tumor metastasis, a low survival rate, and a short survival time. Our results suggest that CD24 may be a valuable molecular marker for predicting prognoses of patients with EOC.

Epithelial ovarian cancer
Back to top